MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
9.28
-0.37
-3.83%
Pre Market: 9.30 +0.02 +0.22% 07:00 05/12 EDT
OPEN
9.67
PREV CLOSE
9.65
HIGH
9.73
LOW
9.18
VOLUME
529
TURNOVER
0
52 WEEK HIGH
16.44
52 WEEK LOW
6.23
MARKET CAP
2.03B
P/E (TTM)
-6.3745
1D
5D
1M
3M
1Y
5Y
1D
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 1d ago
Weekly Report: what happened at OCUL last week (0504-0508)?
Weekly Report · 1d ago
Ocular Therapeutix grants 12 new hires options for 127,650 shares, RSUs for 41,550 shares
PUBT · 3d ago
OCULAR THERAPEUTIX™ REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 3d ago
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 4d ago
Ocular: SOL-1 Success Is Real, But Adoption Risks Keep Me At Hold
Seeking Alpha · 5d ago
Ocular Therapeutix Price Target Maintained With a $18.00/Share by Needham
Dow Jones · 5d ago
Ocular Therapeutix Price Target Maintained With a $30.00/Share by RBC Capital
Dow Jones · 6d ago
More
About OCUL
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.

Webull offers Ocular Therapeutix Inc stock information, including NASDAQ: OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.